ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z

Abstract Number: 0061

Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Abstract Number: 1600

Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?
Abstract Number: 1923

Has the Incidence of Total Joint Arthroplasty in Rheumatoid Arthritis Decreased in the Era of Biologics Use? A Population-based Incident Cohort Study 1995–2015
Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19
Abstract Number: 1605

Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic
Abstract Number: 1271

Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Abstract Number: 1039

Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Abstract Number: 0144

Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada
Abstract Number: 1852

Healthcare Utilization and Economic Burden in Systemic Sclerosis
Abstract Number: 0894

Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Abstract Number: 0670

Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone
Abstract Number: 0101

Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Abstract Number: 0024

Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
Abstract Number: 1927

Heterogeneity of Juvenile Idiopathic Arthritis Synovial Fibroblasts Correlates to Disease Progression and Provides Compelling Diagnostic Data
Abstract Number: 1388

Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus
Abstract Number: 0780

High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 0262

High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
Abstract Number: 1539

High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Abstract Number: 0198

High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases
Abstract Number: 0226

High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
Abstract Number: 0369

High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Abstract Number: 0391

High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
Abstract Number: 0584

High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
Abstract Number: 0715

High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 0042

High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Abstract Number: 1725

Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Abstract Number: 0278

Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
Abstract Number: 1308

Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls
Abstract Number: 0271

Higher Prevalence of Subclinical Atherosclerosis in the First Five Years of Rheumatoid Arthritis Diagnosis
Abstract Number: 0628

Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study
Abstract Number: 0970

Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Abstract Number: 1839

Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
Abstract Number: 0322

Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Abstract Number: 0310

Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome
Abstract Number: 0052

HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
Abstract Number: 0493

Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study
Abstract Number: 0132

Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Abstract Number: 0381

How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Abstract Number: 0909

How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Abstract Number: 1334

How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Abstract Number: 0606

How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines
Abstract Number: PP07

How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Abstract Number: 1055

How to Optimize E-Recruitment Strategies: Lessons Learned from over 3000 Participants in an International Arab Online Study
Abstract Number: 0984

Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Abstract Number: 1431

Human TLR8 Leads to Fatal Anemia Due to Ineffective Erythropoiesis in Bone Marrow Erythroblastic Islands in Murine SLE
Abstract Number: L18

Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Abstract Number: 0009

Humoral Immune Responses to SARS-CoV2 Infections and upon Vaccination Against SARS-CoV2
Abstract Number: 1762

Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications
Abstract Number: 1753

Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Abstract Number: 1462

Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
Abstract Number: 0206

Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Abstract Number: 1875

Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole
Abstract Number: 0578

Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Abstract Number: 0394

Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon
Abstract Number: 1566

Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Abstract Number: 0972

Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis

Jump to: View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].